Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells

International Journal of Cancer

Volumn 137, Issue 9, 2015, Pages 2234-2242

  Göckeritz, Elisa ^a,b   Kerwien, Susan ^a   Baumann, Michael ^a   Wigger, Marion ^a   Vondey, Verena ^a,b   Neumann, Lars ^a,b   Landwehr, Thomas ^a   Wendtner, Clemens M ^a   Klein, Christian ^c   Liu, Ningshu ^d   Hallek, Michael ^a,b   Frenzel, Lukas P ^a,b   Krause, Günter ^a,b  

^a Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Roche Pharmaceutical Research and Early Development   (Switzerland)

^d BAYER PHARMA AG   (Germany)

Author keywords

apoptosis; chronic lymphocytic leukemia; kinase inhibitors; monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; COPANLISIB; DUVELISIB; IDELALISIB; OBINUTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLINOPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-4-YL)PYRIMIDINE-5-CARBOXAMIDE; ANTINEOPLASTIC AGENT; CXCL12 PROTEIN, HUMAN; IPI-145; ISOENZYME; ISOQUINOLINE DERIVATIVE; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW STROMA CELL; CANCER INHIBITION; CELL MIGRATION; CELL SURVIVAL; CHEMOTAXIS; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; IC50; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHEMOKINE CXCL12; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; ISOQUINOLINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PURINES; PYRIMIDINES; QUINAZOLINES; QUINAZOLINONES; SIGNAL TRANSDUCTION;

EID: 84939267232     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29579     Document Type: Article

References (49)

1. Chiorazzi N, Rai KR, Ferrarini M,. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-15.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-74.
3. Cheson BD, Byrd JC, Rai KR, et al., Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30: 2820-2.
4. Wiestner A,. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012; 120: 4684-91.
5. Young RM, Staudt LM,. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-43.
6. Hallek M,. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013; 122: 3723-34.
7. Ringshausen I, Schneller F, Bogner C, et al., Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase cdelta. Blood 2002; 100: 3741-8.
8. Cuni S, Perez-Aciego P, Perez-Chacon G, et al., A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18: 1391-400.
9. Vanhaesebroeck B, Leevers SJ, Ahmadi K, et al., Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535-602.
10. Cantley LC,. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7.
11. Hennessy BT, Smith DL, Ram PT, et al., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
12. Marone R, Cmiljanovic V, Giese B, Wymann MP,. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.
13. Workman P, Clarke PA, Raynaud FI, van Montfort RL,. Drugging the pi3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70: 2146-57.
14. Courtney KD, Corcoran RB, Engelman JA,. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-83.
15. Jabbour E, Ottmann OG, Deininger M, Hochhaus A,. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 2014; 99: 7-18.
16. Fruman DA, Rommel C,. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-56.
17. Niedermeier M, Hennessy BT, Knight ZA, et al., Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit cxcr4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113: 5549-57.
18. Popal W, Boucas J, Peer-Zada AA, Herling M,. Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51: 1375-8.
19. de Frias M, Iglesias-Serret D, Cosialls AM, et al., Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells. Br J Haematol 2010; 150: 108-11.
20. Chapman CM, Sun X, Roschewski M, et al., ON 01910.na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012; 18: 1979-91.
21. Amrein L, Shawi M, Grenier J, et al., The phosphatidylinositol-3 kinase I inhibitor bkm120 induces cell death in B-chronic lymphocytic leukemia cells in-vitro. Int J Cancer 2013; 133: 247-52.
22. Rosich L, Saborit-Villarroya I, Lopez-Guerra M, et al., The phosphatidylinositol-3-kinase inhibitor NVP-bkm120 overcomes resistance signals derived from microenvironment by regulating the akt/FoxO3a/bim axis in chronic lymphocytic leukemia cells. Haematologica 2013; 98: 1739-47.
23. Ramadani F, Bolland DJ, Garcon F, et al., The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal 2010; 3: ra60
24. Herman SE, Gordon AL, Wagner AJ, et al., Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-88.
25. Lannutti BJ, Meadows SA, Herman SE, et al., CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-4.
26. Herman SE, Johnson AJ,. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 4013-8.
27. Hoellenriegel J, Meadows SA, Sivina M, et al., The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-12.
28. Furman RR, Sharman JP, Coutre SE, et al., Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
29. Winkler DG, Faia KL, DiNitto JP, et al., PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013; 20: 1364-74.
30. IPI-145 Shows Promise in CLL Patients. Cancer Discov 2014; 4: 136.
31. Glauer J, Pletz N, Schon M, et al., A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J 2013; 3: e141
32. Liu N, Rowley BR, Bull CO, et al., BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther 2013; 12: 2319-30.
33. Will M, Qin AC, Toy W, et al., Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 2014; 4: 334-47.
34. Patnaik A, Ramanathan RK, Appleman LJ, et al., Phase I study of intravenous PI3K inhibitor bay 80-6946: preliminary activity in patients with relapsed Non-hodgkin lymphoma (NHL) treated in an MTD expansion cohort. Blood 2012; 120: 3704.
35. Patnaik A, Ramanthan RK, Appleman LJ, et al., Phase I study of intravenous PI3K inhibitor BAY 80-6946: preliminary activity in patients with relapsed non Hodgkin lymphoma (NHL) treated in an MTD expansion cohort (ASH abstract 3704). Blood 2012; 120(21 suppl).
36. Dreyling M, Morschhauser F, Bron D, et al., Preliminary results of a phase II study of single agent Bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma (ASH abstract 87). Blood 2013; 122 (21 suppl).
37. Goede V, Fischer K, Busch R, et al., Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-10.
38. Kuckertz M, Patz M, Veldurthy A, et al., Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. Onkologie 2012; 35: 420-6.
39. Subramaniam PS, Whye DW, Efimenko E, et al., Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell 2012; 21: 459-72.
40. Iyengar S, Clear A, Bodor C, et al., P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013; 121: 2274-84.
41. Tabe Y, Jin L, Konopleva M, et al., Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematol 2014; 131: 59-69.
42. Hofmann C, Stuhmer T, Schmiedl N, et al., PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. Br J Haematol 2014; 166: 529-39.
43. Sahin I, Moschetta M, Mishima Y, et al., Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer J 2014; 4: e204
44. Dong S, Guinn D, Dubovsky JA, et al., IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 2014; 124: 3583-6.
45. Kurtova AV, Balakrishnan K, Chen R, et al., Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009; 114: 4441-50.
46. Seiffert M, Stilgenbauer S, Dohner H, Lichter P,. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007; 21: 1977-83.
47. Patz M, Isaeva P, Forcob N, et al., Comparison of the in vitro effects of the anti-cd20 antibodies rituximab and ga101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295-306.
48. Bojarczuk K, Siernicka M, Dwojak M, et al., Bcell receptor pathway inhibitors affect cd20 levels and impair antitumor activity of anti-cd20 monoclonal antibodies. Leukemia 2014; 28: 1163-7.
49. Da Roit F, Engelberts PJ, Taylor RP, et al., Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic cd20 antibodies: implications for combination therapy. Haematologica 2015; 100: 77-86.